Shahbaz Malik, MD
Medical Oncology · Austin, TXNPI 1518125830
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,070 of the $1,700 with a category attached, or 62.9%. 14 manufacturers reported payments, led by Arthrex at 43.8% of the total. Reporting peaked in 2019 at $864 and has fallen 88.8% since, to $96 in 2025. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 45 payments — averaging $37.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$744
- Legend Biotech USA Inc.$180
- Johnson & Johnson$167
- Chiesi USA, Inc.$140
- Bristol Myers Squibb$74
- Novartis$70
- plus $325 from 8 others
Across 92 payments — averaging $2976.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$204K
- AbbVie$70K
What the payments were for
- Travel & lodging$53131%
- Food & beverage$1,07063%
- Education$996%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 14 | $744 |
| Legend Biotech USA Inc. | 6 | $180 |
| Johnson & Johnson | 4 | $167 |
| Chiesi USA, Inc. | 1 | $140 |
| Bristol Myers Squibb | 3 | $74 |
| Novartis | 3 | $70 |
| Janssen Scientific Affairs, LLC | 2 | $65 |
| Astellas Pharma US Inc | 3 | $64 |
| Teva Pharmaceuticals USA, Inc. | 3 | $52 |
| Amgen | 1 | $43 |
| Verastem, Inc. | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Sanofi | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,700 in reported general payments places this provider in the 30th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 25 | $1,277 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Austin
- Sue EckhardtAustin$1.5M
- Miguel AlbinoAustin$322K
- Jason MelearAustin$229K
- Andrew BrennerAustin$125K
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.